ProNeurix

ProNeurix is a preclinical-stage biotechnology company dedicated to developing small molecule therapeutics for peripheral nerve injuries and neuropathies. The company was established through Bluefield Innovations, a strategic partnership between Johns Hopkins University and Deerfield Management, to commercialize the research of Dr. Ahmet Hoke. ProNeurix's primary focus is on inhibiting axonal degeneration, a key pathological process in various neurological conditions, including chemotherapy-induced peripheral neuropathy (CIPN). By targeting specific molecular pathways involved in nerve damage, the company aims to provide first-in-class treatments that promote nerve survival and functional recovery. The company's lead programs leverage novel insights into the SARM1 pathway to prevent the breakdown of axons following injury or toxic insult.